Results 161 to 170 of about 34,934 (250)

The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands. [PDF]

J Clin Transl Endocrinol
de Jongh D, Bunnik E, Ozcan B, Zietse R, Massey E, VANGUARD consortium.   +5 more
europepmc   +1 more source

Role of glutathione and cysteine in acrylamide metabolism during in vitro and in vivo digestion

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Background Acrylamide, a probable human carcinogen found in thermally processed potato products, is reactive towards amino and thiol compounds. This reactivity suggests acrylamide might react with them in the gastrointestinal tract resulting in mitigation of associated risk with acrylamide.
Burçe Ataç Mogol, Choong‐In Yun, Aytül Hamzalıoğlu, Selin Çakmak, Yeşim Şensoy, Nazmiye Çitler, Eunjung Lee, Shin Young Park, Junwon Byun, Young‐Jun Kim, Sanguine Byun, Vural Gökmen   +11 more
wiley   +1 more source

Effects of an artificial pancreas on postoperative inflammation in patients with esophageal cancer. [PDF]

BMC Surg
Miyauchi R, Miki Y, Kasashima H, Fukuoka T, Yoshii M, Tamura T, Shibutani M, Toyokawa T, Lee S, Maeda K.   +9 more
europepmc   +1 more source

Whole‐Genome Bisulfite Sequencing Identifies Blood‐Based DNA Methylation Biomarker for Hepatocellular Carcinoma

Molecular Carcinogenesis, EarlyView.
ABSTRACT Functional DNA methylation abnormalities are a hallmark of human cancers and may be a promising biomarker for their early diagnosis. Moreover, the largest methylation differences can improve the sensitivity of noninvasive diagnoses of solid tumors.
Junsheng Zhao, Sijia Shen, Junjie Zhang, Ying Xu, Jing Peng, Hainv Gao, Lanjuan Li   +6 more
wiley   +1 more source

Themes, Rates, and Risk of Adverse Events of the Artificial Pancreas in the United States Using MAUDE. [PDF]

Ann Biomed Eng
Ferguson AM, Lin AC.
europepmc   +1 more source

White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation

Med Research, EarlyView.
White adipose tissue undergoes browning under endogenous and exogenous stimuli, primarily regulated by core molecules such as PRDM16 and UCP1. It exhibits a double‐edged sword effect in metabolic diseases and tumors: while mitigating metabolic disease impacts and suppressing early‐stage tumors through nutritional competition, it may accelerate cachexia
Yingjiao Wang, Diyuan Zhang, Yuqin Zhou, Ling Qian, Yan Wang, Lei Peng, Min Zhao, Hao Tian, Zhenyu Wu, Aiqi Tang, Minghao Sun, Yi Zhang, Xiaowei Qi   +12 more
wiley   +1 more source

NIH Fifth Artificial Pancreas Workshop 2023: Meeting Report: The Fifth Artificial Pancreas Workshop: Enabling Fully Automation, Access, and Adoption. [PDF]

J Diabetes Sci Technol
Aaron RE, Tian T, Yeung AM, Huang J, Arreaza-Rubín GA, Ginsberg BH, Kompala T, Lee WA, Kerr D, Colmegna P, Mendez CE, Muchmore DB, Wallia A, Klonoff DC.   +13 more
europepmc   +1 more source

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach

Obesity, EarlyView.
Guidance recommendations by TOS/OMA/OAC for the use of obesity medications to treat obesity and its complications. ABSTRACT Background Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated.
Lydia Alexander, Jonathan Q. Purnell, Karlijn Burridge, Marc‐André Cornier, Angela Golden, Deborah Bade Horn, Michelle Look, Joe Nadglowski, Camila Ávila‐Oliver, Francisco Novillo, Ana María Rojas‐Gómez, Brad Hussey, Ximena Ramos Salas   +12 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source